Publicacions en què col·labora amb Enrique de Alava (19)

2019

  1. Preclinical efficacy of endoglin-targeting antibody–drug conjugates for the treatment of Ewing sarcoma

    Clinical Cancer Research, Vol. 25, Núm. 7, pp. 2228-2240

2016

  1. Molecular pathology of bone and soft tissue tumors

    The Molecular Basis of Human Cancer (Springer New York), pp. 623-655

  2. Proteomic Profiling of Ewing Sarcoma Reveals a Role for TRAF6 in Proliferation and Ribonucleoproteins/RNA Processing

    Journal of Proteomics & Bioinformatics, Vol. 09, Núm. 06

2015

  1. The PARP inhibitor olaparib enhances the sensitivity of Ewing sarcoma to trabectedin

    Oncotarget, Vol. 6, Núm. 22, pp. 18875-18890

  2. Trabectedin efficacy in Ewing sarcoma is greatly increased by combination with anti-IGF signaling agents

    Clinical Cancer Research, Vol. 21, Núm. 6, pp. 1373-1382

2014

  1. Characterization of human mesenchymal stem cells from Ewing sarcoma patients. Pathogenetic implications

    PLoS ONE, Vol. 9, Núm. 2

  2. Innovative therapies in ewing sarcoma

    Advances in Anatomic Pathology, Vol. 21, Núm. 1, pp. 44-62

2013

  1. Fluorescence in situ hybridization analysis of CCND3 gene as marker of progression in bladder carcinoma

    Journal of Biological Regulators and Homeostatic Agents, Vol. 27, Núm. 2, pp. 559-567

  2. The calcium-sensing receptor is silenced by genetic and epigenetic mechanisms in unfavorable neuroblastomas and its reactivation induces ERK1/2-dependent apoptosis

    Carcinogenesis, Vol. 34, Núm. 2, pp. 268-276

  3. WEE1 accumulation and deregulation of S-phase proteins mediate MLN4924 potent inhibitory effect on Ewing sarcoma cells

    Oncogene, Vol. 32, Núm. 11, pp. 1441-1451

2012

  1. 1q gain and CDT2 overexpression underlie an aggressive and highly proliferative form of Ewing sarcoma

    Oncogene, Vol. 31, Núm. 10, pp. 1287-1298

2011

  1. IGF1R signaling in Ewing Sarcoma is shaped by clathrin-/caveolin-dependent endocytosis

    PLoS ONE, Vol. 6, Núm. 5

2010

  1. Cyclin D3 gene amplification in bladder carcinoma in situ

    Virchows Archiv, Vol. 457, Núm. 5, pp. 555-561

  2. The clinical relevance of molecular genetics in soft tissue sarcomas

    Advances in Anatomic Pathology, Vol. 17, Núm. 3, pp. 162-181

2009

  1. Advances in Ewing's sarcoma research: Where are we now and what lies ahead?

    Cancer Research, Vol. 69, Núm. 18, pp. 7140-7150

  2. Stable interference of EWS-FLI1 in an Ewing sarcoma cell line impairs IGF-1/IGF-1R signalling and reveals TOPK as a new target

    British Journal of Cancer, Vol. 101, Núm. 1, pp. 80-90

2008

  1. A pivotal role for heat shock protein 90 in Ewing sarcoma resistance to anti-insulin-like growth factor 1 receptor treatment: In vitro and in vivo study

    Cancer Research, Vol. 68, Núm. 15, pp. 6260-6270

  2. Targeting sarcomas: therapeutic targets and their rational

    Seminars in Diagnostic Pathology, Vol. 25, Núm. 4, pp. 304-316

2006

  1. Insulin-like growth factor I receptor pathway inhibition by ADW742, alone or in combination with imatinib, doxorubicin, or vincristine, is a novel therapeutic approach in Ewing tumor

    Clinical Cancer Research, Vol. 12, Núm. 11 I, pp. 3532-3540